Cipla rises after receiving USFDA nod for generic version of Revlimid

7 Sep 2022 , 02:42 PM

Ciplas Lenalidomide capsules are AB-rated therapeutic equivalent generic version of Bristol Myers Squibbs (Celgene) Revlimid (Lenalidomide) capsules. Lenalidomide is an immunomodulatory prescription drug which is indicated for several hematological malignancies in adults such as Multiple Myeloma, Myelodysplastic syndromes, Mantle cell lymphoma, Follicular lymphoma, and Marginal Zone lymphoma. Depending on the type of cancer, it can be used as monotherapy or combination as a part of first line regimen, maintenance regimen or relapsed settings. According to IQVIA (IMS Health), Revlimid (Lenalidomide) capsules had US sales of approximately $2.58 billion for the 12-month period ending June 2022. The pharma company said that the product will be available for shipping soon. Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. The companys consolidated net profit slipped 4% to Rs 686.40 crore on 2.3% decline in total revenue from operations to Rs 5,375.19 crore in Q1 FY23 over Q1 FY22. Powered by Capital Market – Live News